Drug approval decisions garner big headlines, but savvy and successful biotech investors know that making smart trading decisions ahead of important clinical trial results is the ticket to banking serious coin. The market value of Vertex Pharmaceuticals(VRTX_) has jumped by $5 billion in the past three weeks based solely on positive, interim results from a phase II cystic fibrosis trial. That stands in stark contrast to Vertex’s falling stock price following the approval of its hepatitis C drug Incivek.
